¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Stickler syndrome, type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • cat-eye syndrome
    °í¾çÀÌ´«ÁõÈıº
  • cauda equina syndrome
    ¸»ÃÑÁõÈıº, ¸¶¹ÌÁõÈıº
  • central cord syndrome
    Áß½Éô¼öÁõÈıº
  • central pain syndrome
    ÁßÃßÅëÁõÁõÈıº
  • Chinese restaurant syndrome
    Áß±¹À½½ÄÁõÈıº
  • camptomelic syndrome
    ±¼ÁöÁõÈıº
  • chromosomal breakage syndrome
    ¿°»öüÆÄ¼ÕÁõÈıº
  • chronic fatigue syndrome
    ¸¸¼ºÇÇ·ÎÁõÈıº
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • dry eye syndrome
    °Ç¼º¾ÈÁõÈıº, ¾È±¸°ÇÁ¶Áõ
  • dumping syndrome
    ºü¸¥ºñ¿òÁõÈıº, ´ýÇÎÁõÈıº
  • defibrination syndrome
    Å»¼¶À¯¼ÒÁõÈıº, Å»ÇǺ기ÁõÈıº
  • deficit syndrome
    °áÇÌÁõÈıº
  • dysarthria clumsy hand syndrome
    Á¶À½Àå¾Ö¼­Å÷¼ÕÁõÈıº
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • central cord syndrome
    Áß½Éô¼öÁõÈıº
  • central pain syndrome
    ÁßÃßÅëÁõÁõÈıº
  • cerebrovascular syndrome
    ³úÇ÷°üÁõÈıº
  • Chinese restaurant syndrome
    Áß±¹À½½ÄÁõÈıº
  • chromosomal breakage syndrome
    ¿°»öüÆÄ¼ÕÁõÈıº, ¿°»öüºÒ¾ÈÁ¤ÁõÈıº
  • chronic fatigue syndrome
    ¸¸¼ºÇÇ·ÎÁõÈıº
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • clinical syndrome
    ÀÓ»óÁõÈıº
  • clumsy child syndrome
    µÐÇѾƵ¿ÁõÈıº
  • clumsy hand syndrome
    ¼­Å÷¼ÕÁõÈıº
  • co-contraction syndrome
    µ¿½Ã¼öÃàÁõÈıº
  • combined immunodeficiency syndrome
    º¹Çո鿪°áÇÌÁõÈıº
  • compartment syndrome
    ±¸È¹ÁõÈıº
  • complex regional pain syndrome
    º¹ÇÕ±¹¼Òµ¿ÅëÁõÈıº
  • compression syndrome
    ¾Ð¹ÚÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Charlins syndrome
    »þ¸¦·©ÁõÈıº.
  • Chauffard-Still syndrome
    ¼îÆÄ¸£-½ºÆ¿ÁõÈıº.
  • Chediak-Higashi syndrome
    ¼¼µð¾ÆÅ©-È÷°¡½Ã ÁõÈıº
  • Chediak-Higashi syndrome
    ¼¼µð¾ÆÅ©-È÷°¡½ÃÁõÈıº.
  • Chilaiditis syndrome
    ų¶óÀ̵ðƼÁõÈıº.
  • Chronic fatigue syndrome
    ¸¸¼ºÇÇ·Î ÁõÈıº
  • Churg-Strauss syndrome
    Ãʱ×-½ºÅä¶ó¿ì½º ÁõÈıº
  • Cockayne syndrome
    ÄÚÄÉÀÎ ÁõÈıº(~ ñøý¦ÏØ)
  • Cockaynes syndrome
    ÄÚÄÉÀÎ ÁõÈıº
  • Coffin-Lowry syndrome
    ÄÚÇÉ-·Î¸® ÁõÈıº
  • Coffin-Siris syndrome
    ÄÚÇÉ-½Ã¸®½º ÁõÈıº
  • Cogan-Reese syndrome
    ÄÚ°£-¸®½ºÁõÈıº
  • Conn syndrome
    ÄÜÁõÈıº
  • Conns syndrome
    ÄÜÁõÈıº.
  • Conradi syndrome => chondrodysplasia calcificans congenita
    ¼±Ãµ¼º Ä®½·È­ ¿¬°ñ ÀÌÇü¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
  • muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • on off type
    Á¡¸êÇü(ïÇØþúþ).
  • on type
    Áß½ÉÇü.
  • onion skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • organic reaction type
    ±âÁú¼º ¹ÝÀÀÇü(¡­Úãëëúþ).
  • ovulatory type
    ¹è¶õÇü
  • particle, C-type
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
  • personality, type A
    AÇü ÀΰÝ
  • personality, type B
    BÇü ÀΰÝ
  • phage type
    ÆÄÁöÇü
  • phage type
    ÆÄÁöÇü(¡­úþ).
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PS pacemaker syndrome; paired stimulation; paradoxical sleep; paraspinal; parasympathetic; Parkinson sy...
SSS scalded skin syndrome; secondary Sjogren syndrome; sick sinus syndrome; specific soluble substance; ...
TSST-1 Toxic Shock Syndrome Toxin-1
  = Enterotoxin type F
CNF chronic nodular fibrositis; congenital nephrotic syndrome of the Finnish [type]
CRPS complex regional pain syndrome [type I and II]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
AT1 Angiotensin II receptor type 1
AT1 Angiotensin type 1 receptor
AT2 Angiotensin II type 2
AT2 Angiotensin II type 2 receptor
AT(1) Angiotensin type 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • androgen resistance syndrome
    ³²¼º È£¸£¸ó ³»¼º ÁõÈıº, ³²¼º È£¸£¸ó ÀúÇ× ÁõÈıº
  • Angelmans syndrome
    ¾Þ°Ö¸¸ ÁõÈıº
  • anginal syndrome
    Çù½ÉÁõ ÁõÈıº
  • anorexia-cachexia syndrome
    ½Ä¿å ºÎÁø-¾Ç¾×Áú ÁõÈıº
    ½Ä¿å ºÎÁø°ú ¾Ç¾×Áú°£¿¡ ¾ÆÁ÷ ¹àÇôÁöÁö ¾ÊÀº ¾î¶² °ü°è¿¡¼­ ÀϾ´Â ¾ÏÀÇ Àü½Å Áõ»óÀ¸·Î¼­ ¿µ¾ç½ÇÁ¶, üÁß °¨¼Ò, ±ÙÀ° Çã¾à, »ê¼ºÁõ ¹× Áßµ¶ÁõÀÌ Æ¯Â¡ÀÌ´Ù. ½Ä¿å ºÎÁøÀ» ÀÏÀ¸Å°´Â ±Ù°Å·Î´Â ½ÉÇÑ ´ÙÀμº ½ÅÁø´ë»çÀÇ Àå¾Ö°¡ ¾Ç¾×Áú¼º ¼Ò¸ð¸¦ ÀÏÀ¸Å°´Â µ¥ °ü¿©ÇÑ´Ù°í »ý°¢µÈ´Ù. µû¶ó¼­ ½Ã»ó ÇϺο¡ ÀÖ´Â Æ÷¸¸ ÁßÃ߸¦ Á¾¾ç¿¡¼­ ºÐºñµÇ´Â ½Ä¿åºÎÁø È£¸£¸óÀÌ ÀÚ±ØÇÏ¿© ½Ä¿åÀ» ¾ø¾Ö ½Ä¿åºÎÁøÀ» ÀÏÀ¸Å²´Ù´Â °ÍÀÌ´Ù.
  • anterior choroidal artery occlusion syndrome
    Àü¸Æ¶ô Ãѵ¿¸Æ Æó¼â ÁõÈıº
  • anterior cornual syndrome
    Àü°¢ ÁõÈıº
    ô¼ö Àü°¢ÀÇ »óÇØ¸¦ ³ªÅ¸³»°í, ¿îµ¿ ¸¶ºñ¿Í ±Ù À§ÃàÀÌ Æ¯Â¡ÀÌ´Ù.
  • anterior spinal artery syndrome
    Àüô¼ö µ¿¸Æ ÁõÈıº
  • anterior spinal syndrome
    Àü»è ÁõÈıº
  • anticholinergic syndrome
    Ç×Äݸ°¼º ÁõÈıº
    °æÁõ °íÇ÷¾Ð°ú ºó¸ÆÀÌ ÀϹÝÀûÀ̸ç, ü¿ÂÀº ÈçÈ÷ »ó½ÂµÈ´Ù. µ¿°øÀº ±¤¹üÀ§ÇÏ°Ô È®ÀåµÇ¾î ÀÖ´Ù. ÇǺδ ¹ßÀûµÇ¾î ÀÖ°í ¶ß°Ì°í °ÇÁ¶ÇÏ´Ù. Àå ¿îµ¿Àº °¨¼ÒÇÏ°í ¿ä Á¤Ã¼
  • anxiety syndrome
    °í¹Î ÁõÈıº, ºÒ¾È ÁõÈıº
    Á¤½ÅÀû °í¹Î¿¡ ¼ö¹ÝÇÏ´Â ÁõÈıºÀ¸·Î, ½É°èÇ×Áø, È£Èí°ï¶õ, ¹ßÇÑ, ¾È»ö â¹é, °øÆ÷ µîÀ» ³ªÅ¸³½´Ù.
  • aortitis syndrome
    ´ëµ¿¸Æ¿° ÁõÈıº
  • apallic syndrome
    ¹«½É ÁõÈıº
  • apathetic-akinetic syndrome
    ¹«°¨µ¿-¹«µ¿ÀÛ ÁõÈıº
  • Apert syndrome
    ¿¡ÆÛÆ® ÁõÈıº, ¾ÆÆä¸£Æ® ÁõÈıº
    ÀÓ»óÀûÀ¸·Î µÎ°³°ñ ºÀÇÕÀÇ Á¶±â Æó¼â·Î ÀÎÇÑ µÎ°³ ±âÇü, ¾È¸é Á߾ӺΠÇü¼º ºÎÀü, ¾çÃø¼º ÇÕÁöÁõÀ¸·Î Á¤ÀǵȴÙ. µå¹® Àå¾Ö·Î¼­ ¶§·Î »ó¿°»öü ¿ì¼º À¯ÀüÀÌ °üÂûµÇ±âµµ Çϳª º¸ÅëÀº »ê¹ßÀûÀÎ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ ¹ß»ýµÈ´Ù.
  • arthritis-dermatitis syndrome
    °üÀý¿°-ÇǺο° ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
delayed type hypersensitivity <immunology> Hypersensitivity (increased reaction by the body to a foreign substance such as an antigen or allergen) that does not appear until 24 to 48 hours after the body is exposed to the foreign substance.
(09 Oct 1997)
Swiss type agammaglobulinaemia Group of rare congenital disorders characterised by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an x-linked or autosomal recessive defect. About half of the patients with autosomal recessive scid are deficient in the enzyme adenosine deaminase.
(12 Dec 1998)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
diabetes, type 1 Insulin dependent diabetes or juvenile diabetes.
(12 Dec 1998)
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á